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INTRODUCTION
Chronic kidney disease (CKD) is an increasing global health 
problem.1 In Korea, the prevalence of CKD was 8.2% from 2011 
to 2013 according to the Korean National Health and Nutrition 
Examination Survey, and it is steadily growing.2 As CKD has be-
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come more common, the number of patients with end-stage 
renal disease (ESRD) has also rapidly increased.3,4 Because the 
cost of ESRD treatment, including dialysis and kidney trans-
plantation, is quite high and constantly rising, it has become a 
serious social problem in many countries.5 Therefore, prevent-
ing or slowing disease progression at the earliest stage possible 
is important in the treatment of patients with CKD.
Previous studies have shown that management of factors 
associated with renal deterioration, such as high blood pres-
sure (BP), uncontrolled diabetes, and proteinuria, could delay 
disease progression.6-8 Angiotensin-converting enzyme inhib-
itors and angiotensin II receptor blockers are considered im-
portant agents that slow disease exacerbation through their 
renoprotective effects.9,10 However, disease progression is not 
completely prevented, and many patients with CKD develop 
ESRD. Therefore, a new therapeutic option with a different 
mechanism is needed in this population.
Serum levels of indoxyl sulfate (IS), a uremic toxin, are elevat-
ed in patients with CKD and appear to be correlated with dis-
ease progression.11 Oral carbon adsorbents may reduce circulat-
ing uremic toxins including IS and delay renal deterioration.12 
AST-120 (Kremezin®, Kureha Chemical Industry Co., Ltd., To-
kyo, Japan), a granule type adsorbent, was approved in 1991 for 
delaying the initiation of dialysis and improving uremic symp-
toms in patients with CKD.13-17 Despite its potential effects, the 
clinical use of AST-120 has some limitations: many patients find 
AST-120 difficult to tolerate because of its unpleasant texture 
and taste. It is also difficult to take the exact prescribed amount 
because of granule retention in the oral cavity and because of 
drug loss that occurs when packing the granules in a wrapper. 
Further, there is an additional cost for purchasing the wrapper 
used to assist consumption of the granules. These limitations 
could reduce patient adherence to granule adsorbent treatment, 
which could, in turn, reduce drug efficacy.
DW-7202 (Renamezin®, Daewon Pharmaceutical Co., Ltd., 
Seoul, Korea) is a new oral adsorbent developed using a furan 
resin-based formula, unlike the phenol-based formula used in 
existing oral adsorbents. We conducted a phase IV clinical trial 
to evaluate patient preference for and adherence to DW-7202 
versus AST-120 therapy and to compare the efficacy and safety 
of the two oral adsorbents in patients with pre-dialysis CKD.
MATERIALS AND METHODS 
Study design 
We performed a prospective, randomized, open-label, active-
controlled, two-way crossover study in patients aged 20–75 
years with pre-dialysis CKD in seven medical facilities in Ko-
rea between December 2015 and December 2016. All subjects 
provided written consent before participating. The trial was 
registered on Clinical Trials.gov (NCT02681952), and the 
study start date was February 15, 2016. Sample size calcula-
tion was conducted to determine the number of participants 
who would prefer a capsule type adsorbent to a granule type 
adsorbent. Assuming a preference for the capsule type of 65%, 
we selected 114 subjects under the following conditions: 5% α 
error (two-sided) and 90% statistical power. We finally set the 
number of subjects at 152 (76 patients per group) to compen-
sate for a dropout rate of 25%.
Fig. 1 shows the study design. After a 4-week screening pe-
riod, we used a computer-generated randomization process 
(SAS 9.4 software; SAS Institute, Cary, NC, USA) to randomly 
allocate subjects who satisfied the final selection criteria into 
two groups (1:1 ratio). One group received the capsule type 
adsorbent, DW-7202 (capsule to granule group), and the oth-
er received the granule type adsorbent, AST-120 (granule to 
capsule group). After 12 weeks, participants switched to the 
other type of adsorbent for the next 12 weeks. The dose of the 
capsule type adsorbent was seven capsules (2 g) three times 
daily (21 capsules/day). The dose of the granule type adsor-
bent was one pack (2 g) three times daily. Written informed 
consent was obtained from all enrolled individuals in line 
with the Declaration of Helsinki. The study’s protocol was re-
viewed and approved by the Institutional Review Boards of 
the clinical trial centers of each participating institution (Hal-
lym University, Ilsan-Paik Hospital of Inje University, Ewha 
Womans University, Kyunghee University, Hanyang Universi-
ty, Haeundae-Paik Hospital of Inje University, and Yonsei 
University). The methods were carried out in accordance with 
the approved guidelines. 
Study drugs 
DW-7202 consists of black spherical carbon particles approxi-
mately 0.2 to 0.5 mm in diameter. The particles are produced 
from a furan resin-based formula and have a porous structure, 
which determines the adsorption properties. The DW-7202 
used in this study was provided as a capsule containing 285.7 
mg per capsule. Patients took seven capsules to achieve a dose 
of 2 g. AST-120 also consists of black spherical carbon particles; 
however, it is produced from a phenol-based formula. The 
AST-120 used in this study was provided as a granule pack 
containing 2 g. Patients consumed the entire granule pack (2 g) 
for one dose. The same dosage was used for both adsorbents 
because previous in vivo experiments showed that the adsorp-
tion capacity of DW-7202 was equivalent to that of AST-120 
(Supplementary Table 1, only online) and that the ability of 
DW-7202 to reduce serum levels of IS was also equivalent to 
that of AST-120 (Supplementary Fig. 1, only online) (unpub-
lished data). 
Participants
We reviewed outpatient medical records at participating facili-
ties to identify eligible patients. Eligibility criteria included a 
stable serum creatinine level (2.0–5.0 mg/dL) and estimated 
glomerular filtration rate (eGFR, 15–60 mL/min/1.73 m2) in 
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the 3-month pre-screening period, no change in CKD treat-
ment in the 4-week pre-screening interval, and no expected 
care plan change during the study. Eligible patients were ex-
cluded if they met any of the following conditions during the 
subsequent 4-week screening period: 1) uncontrolled diabetes 
[hemoglobin A1c (HbA1c) >10% or fasting glucose >180 mg/
dL]; 2) uncontrolled hypertension (systolic BP ≥170 mm Hg or 
diastolic BP ≥100 mm Hg); 3) current infection; 4) hepatic im-
pairment (2.5 times greater than the upper limit of normal as-
partate aminotransferase or alanine aminotransferase levels); 
5) required immunosuppressive agents or kidney transplant; 
6) hospitalized with cardiovascular disease within 3 months 
before screening; 7) inadequate CKD treatment before screen-
ing; 8) malignant tumor; 9) pregnant, lactating, or had a 
chance of becoming pregnant during the study; 10) drug or al-
cohol dependency; 11) taking an oral adsorbent for 3 months 
before screening; 12) participation in another clinical study or 
receiving another study drug; 13) expected to start dialysis 
within 3 months; 14) uncontrolled constipation, peptic ulcer 
disease, or esophageal varix; and 15) gastrointestinal tract ob-
struction.
Preference, efficacy, safety, and adherence 
assessments
Patient preference was the primary outcome and was assessed 
using a questionnaire after the two 12-week periods of drug ad-
ministration. Participants were asked, “Which of the two types 
of adsorbents do you prefer?” They selected one of the following 
answers, taking their overall satisfaction into account: no differ-
ence, capsule type of adsorbent, or granule type of adsorbent. 
We evaluated drug efficacy by analyzing changes in clinical vari-
ables (serum creatinine, IS, cystatin C, and eGFR) after the first 
12-week period. Overall treatment satisfaction was determined 
using a patient global assessment (PGA) scale, which included 
five categories: very bad, bad, neutral, good, and very good. 
Changes in subjective symptoms (anorexia, halitosis, nausea, 
itching, and edema) and PGA scale ratings at the end of the first 
and second 12-week periods were also evaluated as efficacy pa-
rameters (secondary outcomes). The results were summarized 
according to whether the subjective symptoms and PGA scale 
ratings were better or worse after the second 12-week period, 
compared to those after the first 12-week period.
Safety was evaluated by investigating the incidence and types 
Fig. 1. Study design and subject disposition: 153 patients were randomly assigned.
Group A: DW-7202 first
9 dropout
  1 adverse event
  8 withdrawal of consent
(n=63) (n=61)
14 dropout
  1 start dialysis
  1 follow-up loss
  2 adverse events
  10 withdrawal of consent
4 dropout
  2 start dialysis
  2 withdrawal of consent
2 dropout
  1 follow-up loss
  1 withdrawal of consent
Excluded
Not meeting inclusion criteria (n=9) 
Withdrawal of consent (n=4)
Corss-over at 12 weeks





DW-7202 (n=76) AST-120 (n=77)
Group B: AST-120 first
Switch to AST-120 (n=67) Switch to DW-7202 (n=63)
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of adverse events associated with the administration of each 
adsorbent. Additionally, vital sign measurements, laboratory 
tests, and physical examinations were conducted at the end of 
both 12-week periods to evaluate medication safety. Patient ad-
herence to drug treatment was assessed by using the pill count 
technique and estimated by comparing the expected amount 
of drug remaining with the actual amount participants brought 
to the evaluation at the end of each 12-week period. 
Data collection
Baseline demographic data, including age, sex, BP, medical 
history, and current medications, were obtained at the start of 
the first 12-week period. Laboratory tests for hemoglobin, 
electrolytes, uric acid, albumin, total cholesterol, triglycerides, 
high-density lipoprotein cholesterol, HbA1c, serum creati-
nine, cystatin C, and IS were also carried out at that time. We 
calculated eGFR using the Modification of Diet in Renal Dis-
ease equation.18 Serum creatinine, cystatin C, IS, and eGFR 
were re-checked after the first and second 12-week periods to 
assess drug efficacy. The four serum variables were analyzed 
by an outside laboratory (Seoul Central Laboratory, Seoul, 
Korea) to minimize measurement bias. 
Statistical analyses
We performed our safety analysis in the group of participants 
who took a study medication at least once after group alloca-
tion (the safety population). Inter-group comparisons of base-
line demographic and laboratory data were conducted using 
Student’s t-test for numerical variables and Fisher’s exact test 
or a chi-squared test for categorical variables. Patient prefer-
ence was analyzed using the Cochran-Mantel-Haenszel test to 
control for institutional differences in patient preference. In 
analyses of efficacy using clinical variables, the treatment ef-
fect of each type of adsorbent was compared using the Wilcox-
on-signed rank test. For other efficacy analyses, McNemar’s 
test or Prescott’s test was used to evaluate the significance of 
differences in changes in subjective symptoms or PGA scale 
ratings in both groups. Statistical significance was defined as a 
two-tailed p value less than 0.05. All analyses were performed 
using SAS version 9.4 software.
RESULTS
Baseline characteristics
Recruitment began in December 2015, and the study ended in 
December 2016 (the last day on which a participant was seen). 
Of the 166 patients screened at seven study centers, 153 (male, 
65%; mean age, 57.1 years) met the inclusion criteria and were 
randomly assigned to group A (n=76, administration of DW-
7202 followed AST-120) and group B (n=77, administration of 
AST-120 followed DW-7202). Twenty-three patients (group A, 
n=9; group B, n=14) dropped out during the first 12-week peri-
od, and 6 (group A, n=4; group B, n=2) dropped out during the 
second. One hundred twenty-four patients completed the 
study (81.0%; group A, n=63; group B, n=61). Baseline charac-
teristics and laboratory data of the study subjects are shown in 
Table 1 and Table 2, respectively. There were no significant dif-
ferences in demographic and clinical characteristics between 
the two groups. Stage 3 or 4 CKD was present in 96% of all sub-
jects, and there was no significant difference between the two 
groups in terms of CKD stage distribution. There were also no 
significant differences in baseline laboratory data between the 
two groups.
Preference
Results of the preference analyses are presented in Fig. 2. Pref-
erence analyses were conducted in the full analysis set (FAS, 
the group of patients who received at least one dose of the as-
signed drug and whose data on the primary outcome could 
be obtained). One hundred and nineteen patients expressed 
a drug preference, and the group that preferred DW-7202 
(65.5%) was significantly larger than the group that preferred 
AST-120 (34.5%) (p<0.001).
Efficacy
Fig. 3 shows the results of our efficacy analyses. Due to the 
limitations of a crossover study, we evaluated the changes in 
clinical variables between 0 and 12 weeks. After the first 12-
Table 1. Baseline Characteristics of the Study Subjects
Variables
Total Group A Group B
p value
(n=153) (n=76) (n=77)
Age (yr) 57.1±11.4 57.8±10.0   56.4±12.6 0.453
Male sex   100 (65.4) 53 (69.7) 47 (61.0) 0.258
SBP (mm Hg) 129.2±13.2 129.5±13.1 128.9±13.4 0.816
DBP (mm Hg) 74.8±9.1 74.4±9.7 75.2±8.6 0.583
Hypertension   128 (84.8)  67 (88.2) 61 (81.3) 0.174
Diabetes 67 (44.4)  33 (43.4) 34 (45.3) 0.471
Medications
RAS blocker   127 (83.0) 66 (86.8) 61 (79.2) 0.149
CCB 53 (34.6) 26 (34.2) 27 (35.1) 0.523
β-blocker 45 (29.4) 23 (30.3) 22 (28.6) 0.479
Diuretics 28 (18.3) 12 (15.8) 16 (20.8) 0.278
Statin 93 (60.8) 50 (65.8) 43 (55.8) 0.137
CKD stage 0.502
Stage 2 1 (0.7) 0 (0.0) 1 (1.3)
Stage 3 94 (61.4) 48 (63.2) 46 (59.7)
Stage 4 53 (34.6) 27 (35.5) 26 (33.8)
Stage 5 5 (3.3) 1 (1.3) 4 (5.2)
SBP, systolic blood pressure; DBP, diastolic blood pressure; RAS blockers, re-
nin-angiotensin system blocker; CCB, calcium channel blocker; CKD, chronic 
kidney disease.
Data are presented as a mean±standard deviation or number (%). Group A: 
administration of DW-7202 followed AST-120, group B: administration of 
AST-120 followed DW-7202.
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week period, the changes in serum creatinine, cystatin C, and 
eGFR were not significantly different between group A and 
group B. Serum IS levels were significantly lower after the first 
12-week period in both groups, and there was no significant 
between-group difference in the magnitude of this change 
(25.8% decrease in group A and 24.2% decrease in group B). 
Table 3 shows the change in subjective symptoms and PGA 
scale ratings in each group. Subjective symptoms evaluated 
after 12 and 24 weeks were unchanged in most patients, and 
there were no significant between-group differences in the 
proportion of patients who showed subjective symptom im-
provement or worsening. PGA scale ratings assessed after 12 
and 24 weeks were also unchanged in most patients in both 
groups. Furthermore, the proportion of patients whose PGA 
scale ratings changed was not significantly different between 
the groups. All of the above efficacy analyses were also per-
formed in the per protocol set that included only subjects 
without major protocol violations (n=111), and the results 
were the same as those in the FAS cohort.
Adherence 
During the first 12-week period, drug adherence was similar 
Table 2. Laboratory Data of Study Subjects
Variables
Total Group A Group B
p value
(n=153) (n=76) (n=77)
Hemoglobin (g/dL) 12.5±1.9 12.6±1.9 12.3±1.9 0.245
Sodium (mEq/L) 140.3±2.2 140.4±2.1 140.3±2.4 0.821
Potassium (mEq/L) 4.8±0.5 4.7±0.5 4.8±0.5 0.466
Uric acid (mg/dL) 6.9±1.9 6.9±1.9 6.9±1.8 0.788
Albumin (g/dL) 4.1±0.4 4.1±0.4 4.0±0.4 0.791
Total cholesterol (mg/dL) 175.7±37.0 175.7±39.5 175.7±34.7 0.999
Triglyceride (mg/dL) 161.3±103.6 151.8±79.6 170.7±122.6 0.259
HDL-cholesterol (mg/dL) 47.6±13.8 47.8±14.6 47.5±12.9 0.876
HbA1c (%) 6.2±1.1 6.3±1.1 6.2±1.0 0.668
Cystatin C (mg/dL) 2.1±0.6 2.1± 0.6 2.1±0.7 0.840
Indoxyl sulfate (mg/dL) 0.33±0.25 0.32± 0.21 0.34± 0.28 0.549
Creatinine (mg/dL) 2.14±0.70 2.18± 0.75 2.10± 0.66 0.493
eGFR (mL/min/1.73 m2) 37.6±13.4 36.9±13.7 38.3±13.1 0.550
HDL, high-density lipoprotein; eGFR, estimated glomerular filtration rate.
Data are presented as a mean±standard deviation, Group A: administration 
of DW-7202 followed AST-120, group B: administration of AST-120 followed 
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between group A (85.8±3.6%) and group B (83.4±22.9%) (Fig. 
4). During this period, 14 patients (18.2%) in group B dropped 
out, compared to 9 (11.8%) in group A During the first 12-week 
period, drug adherence was similar between group A (85.8± 
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 During taking DW-7202 (n=77)   During taking AST-120 (n=68)  During taking DW-7202 (n=62)   During taking AST-120 (n=74)
Cross-over Cross-over
Table 3. Changes in Subjective Symptoms and PGA Scales
Change




Improved 6 (9.8) 9 (15.5)
No change 54 (88.5) 45 (77.6)
Worsened 1 (1.6) 4 (6.9)
Halitosis 0.052
Improved 7 (11.5) 5 (8.6)
No change 53 (86.9) 45 (77.6)
Worsened 1 (1.6) 8 (13.8)
Nausea 0.733
Improved 2 (3.3) 3 (5.2)
No change 57 (93.4) 53 (91.4)
Worsened 2 (3.3) 2 (3.4)
Itching sense 0.199
Improved 7 (11.5) 3 (5.2)
No change 49 (80.3) 48 (82.8)
Worsened 5 (8.2) 7 (12.1)
Edema 0.167
Improved 8 (13.1)   6 (10.3)
No change 50 (82.0) 44 (75.9)
Worsened 3 (4.9)  8 (13.8)
PGA scales 0.523
Improved 8 (13.1)  8 (13.8)
No change 47 (77.0) 47 (81.0)
Worsened 6 (9.8) 3 (5.2)
PGA, patient global assessment.
Data are presented as a number (%). Group A: administration of DW-7202 
followed AST-120, group B: administration of AST-120 followed DW-7202.
3.6%) and group B (83.4±22.9%). Although there was no statis-
tically significant change in adherence in either group, group 
B showed clinically greater improvement in adherence after 
medication crossover (83.4±22.9% to 90.0±15.1%, p=0.057) than 
group A (85.8±23.6% to 87.7±19.2%, p=0.333).  
Safety
Table 4 shows the incidence of adverse drug events (ADEs) and 
serious adverse events (SAEs) in patients taking each type of 
adsorbent, respectively. During the entire study period, 15 
ADEs were reported in 13 patients taking DW-7202, while 15 
were reported in 14 patients receiving AST-120. The most fre-
quent ADE involved gastrointestinal symptoms after the ad-
ministration of both adsorbent types, including constipation, 
diarrhea, nausea, abdominal discomfort, dyspepsia, abdominal 
pain, and abdominal distension. Two SAEs were reported in 
two patients taking DW-7202, and seven were reported in five 
subjects receiving AST-120. No deaths occurred during the 
study period. In our results, the incident rates of ADEs and SAEs 
were similar during treatment with DW-7202 and AST-120.
DISCUSSION
We compared two types of oral adsorbents and found that the 
new capsule type, DW-7202, showed efficacy and safety simi-
lar to those of the granule type, AST-120, in patients with pre-
dialysis CKD. DW-7202 was preferred by more patients than 
AST-120, and medication adherence was improved in patients 
who switched from AST-120 to DW-7202.
CKD is characterized by renal function deterioration that 
causes a progressive retention of a large amount of various ure-
mic toxins.19 A representative uremic toxin, IS, accumulates in 
the blood and tissue in patients with reduced renal function.20 
Elevated circulating IS contributes to the loss of renal function in 
patients with CKD and plays an important role in their increased 
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Table 4. ADEs and SAE While Taking Each Type of Oral Absorbent
During treatment  
with DW-7202
During treatment  
with AST-120
ADEs
Total 15 cases, 13 patients 15 cases, 14 patients
Constipation 4 cases, 4 patients 4 cases, 4 patients
Abdominal discomfort 3 cases, 3 patients 3 cases, 3 patients
Dyspepsia 1 case, 1 patient 4 cases, 4 patients
Abdominal pain upper 2 cases, 2 patients 0
Diabetic gastropathy 0 1 case, 1 patient
Nausea 1 case, 1 patient 0
Abdominal distension 1 case, 1 patient 0
Diarrhea 1 case, 1 patient 0
Drug eruption 1 case, 1 patient 0
Pruritus 1 case, 1 patient 0
Dizziness 0 1 case, 1 patient
SAE
Total 2 cases, 2 patients 7 cases, 5 patients
Diabetic gastropathy 0 1 case, 1 patient
Nausea 0 1 case, 1 patient
Vomiting 0 1 case, 1 patient
Cellulitis 0 1 case, 1 patient
Pyelonephritis 0 1 case, 1 patient
Dacryostenosis 1 case, 1 patient 0
Hyperkalemia 0 1 case, 1 patient
Transient ischemic attack 1 case, 1 patient 0
Cerebrovascular accident 0 1 case, 1 patient
ADEs, adverse drug events; SAE, severe adverse events.
cardiovascular disease risk.21-26 Thus, a drug capable of adsorb-
ing IS was developed and introduced to treat pre-dialysis CKD.
Previous studies have shown that adsorbents decrease serum 
IS in a dose-dependent manner and that high medication ad-
herence is associated with positive effects including the preven-
tion of IS accumulation and delayed disease progression.27-29 
Therefore, it is important for patients to comply with treatment 
and to take the correct dose. DW-7202 is provided in a form that 
is convenient for patients. Compared to adsorbents that are de-
livered as granules, the capsule type is easier for patients to swal-
low and allows for more exact dosing. Additionally, because the 
granules are sealed within a capsule, patients do not experience 
the unique and unpleasant taste of the medication. Further, ma-
terials (e.g., wrappers) that add to the cost and effort of treat-
ment are not required to facilitate consumption of DW-7202 
capsules. Our patients preferred DW-7202 to AST-120, and treat-
ment adherence was improved when participants switched 
from AST-120 to DW-7202; however, it was difficult to identify 
the factors that influenced patient preference in this study using 
only our simple questionnaire. Despite the possibility of the pill 
burden, the preference for DW-7202 may be a positive finding of 
our study. Therefore, our results suggest that DW-7202, a cap-
sule type adsorbent, could be an effective treatment option for 
patients who cannot tolerate or show poor adherence to granule 
type adsorbent therapy. 
DW-7202 is a new type of adsorbent developed to have high 
adsorption selectivity for uremic toxins, and the compound 
strength is enhanced by a furan resin-based formula. Our 
study showed that there were no significant differences in 
treatment efficacy between the two types of adsorbent. Safety 
analyses showed that the incident rates of ADEs and SAEs 
were similar during treatment with DW-7202 and AST-120. 
Nevertheless, the total incidence of SAEs was lower during 
treatment with DW-7202 than during treatment with AST-120. 
The most frequently occurring ADEs during DW-7202 treat-
ment were gastrointestinal disorders, a finding similar to the 
results of previous studies of AST-120.30,31 Therefore, our results 
indicate that DW-7202 could be considered an alternative to 
granule adsorbents for the treatment of patients with CKD. 
This study had some limitations. First, we used an open-la-
bel design. One of our goals was to evaluate patient prefer-
ence for two different types of adsorbent. Therefore, a double-
blind study was not feasible. Although the primary outcome 
results could be considered as just confirmatory results, this 
study is significant because it is the first clinical study to com-
pare the preference and adherence of two adsorbents. Sec-
ond, since we employed a crossover design that did not have 
a washout period, our ability to evaluate the efficacy and safe-
ty of the adsorbents was limited. At the beginning of the first 
12-week period, the results were fairly reliable because the 
subjects were evenly assigned to both groups. Due to drop out 
and loss to follow-up, the two groups were no longer similar 
when entering the second 12-week period, which could have 
introduced selection bias. Additionally, patients who dropped 
out after beginning dialysis were not included in the analysis, 
which also limited our efficacy and safety assessments. There-
fore, further studies with an adequate washout period are 
needed to compare the efficacy and safety of these adsorbents 
independently under equal conditions. Third, the study peri-
od was not long enough to adequately explore the results of 
slow CKD progression and to fully compare the efficacy and 
safety of the two adsorbents. Furthermore, it is difficult to 
draw conclusions regarding the efficacy and safety of the two 
adsorbents because of the study design, which did not include 
patients with CKD who did not take any adsorbent. Thus, in 
the future, a longer study conducted in a larger population 
that includes non-medicated patients with CKD will be nec-
essary to assess the usefulness of DW-7202 in comparison to 
AST-120. Finally, it was difficult to objectively assess patient 
preference through the simple questionnaire used in this 
study. To assess preference more objectively, the relative de-
sirability of factors affecting patient choices should be investi-
gated. Further studies using more objective methods, such as 
some established rating scales, are required to overcome sub-
jective bias in assessing patient preference.
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Nevertheless, this study is significant because it is the first 
clinical trial to compare the efficacy and safety of the new adsor-
bent DW-7202 with one that is currently prescribed. Although 
some investigations demonstrated equivalent effects of DW-
7202 and AST-120 in reducing IS concentrations, there are few 
published clinical studies reporting the effects of DW-7202 on 
disease progression in patients with CKD. Therefore, this study 
provides an important basis for future DW-7202 trials. 
In conclusion, this study shows the new oral adsorbent 
DW-7202 is preferred to AST-120 in patients with pre-dialysis 
CKD. DW-7202 can be considered an alternative to AST-120 
for patients who cannot tolerate or show poor adherence to 
granule type adsorbent therapy. A future clinical trial aimed at 
showing that higher preference and improved adherence 
positively influence clinical outcomes in patients with CKD is 
warranted to assess the clinical usefulness of DW-7202.
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